HRP20151218T1 - Sredstva za induciranje apoptoze za lijeäśenje raka te imunih i autoimunih bolesti - Google Patents
Sredstva za induciranje apoptoze za lijeäśenje raka te imunih i autoimunih bolesti Download PDFInfo
- Publication number
- HRP20151218T1 HRP20151218T1 HRP20151218TT HRP20151218T HRP20151218T1 HR P20151218 T1 HRP20151218 T1 HR P20151218T1 HR P20151218T T HRP20151218T T HR P20151218TT HR P20151218 T HRP20151218 T HR P20151218T HR P20151218 T1 HRP20151218 T1 HR P20151218T1
- Authority
- HR
- Croatia
- Prior art keywords
- amino
- phenyl
- sulfonyl
- ylmethyl
- benzamide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
- C07D295/112—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
- C07C311/51—Y being a hydrogen or a carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/195—Radicals derived from nitrogen analogues of carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/56—Ring systems containing bridged rings
- C07C2603/58—Ring systems containing bridged rings containing three rings
- C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
- C07C2603/74—Adamantanes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrane Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Furan Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31757510P | 2010-03-25 | 2010-03-25 | |
| EP11709579.4A EP2550258B1 (en) | 2010-03-25 | 2011-03-10 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| PCT/US2011/027895 WO2011119345A2 (en) | 2010-03-25 | 2011-03-10 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20151218T1 true HRP20151218T1 (hr) | 2016-01-01 |
Family
ID=43858249
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20151218TT HRP20151218T1 (hr) | 2010-03-25 | 2011-03-10 | Sredstva za induciranje apoptoze za lijeäśenje raka te imunih i autoimunih bolesti |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US8188077B2 (enExample) |
| EP (3) | EP2957558A3 (enExample) |
| JP (1) | JP5959501B2 (enExample) |
| KR (1) | KR20130040834A (enExample) |
| CN (2) | CN105218483A (enExample) |
| AU (1) | AU2011229862B2 (enExample) |
| BR (1) | BR112012024382A2 (enExample) |
| CA (1) | CA2792276A1 (enExample) |
| DK (1) | DK2550258T3 (enExample) |
| ES (1) | ES2553143T3 (enExample) |
| HK (2) | HK1200444A1 (enExample) |
| HR (1) | HRP20151218T1 (enExample) |
| HU (1) | HUE026241T2 (enExample) |
| IL (2) | IL221771A (enExample) |
| MX (1) | MX2012011086A (enExample) |
| NZ (2) | NZ602055A (enExample) |
| PL (1) | PL2550258T3 (enExample) |
| PT (1) | PT2550258E (enExample) |
| RS (1) | RS54388B1 (enExample) |
| RU (2) | RU2568611C2 (enExample) |
| SG (2) | SG10201406608YA (enExample) |
| SI (1) | SI2550258T1 (enExample) |
| SM (1) | SMT201600016B (enExample) |
| TW (2) | TW201623291A (enExample) |
| WO (1) | WO2011119345A2 (enExample) |
| ZA (1) | ZA201206837B (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120156134A1 (en) | 2007-12-20 | 2012-06-21 | Shayne Squires | Compositions and methods for detecting or eliminating senescent cells to diagnose or treat disease |
| NZ593593A (en) | 2009-01-19 | 2013-11-29 | Abbvie Inc | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US9034875B2 (en) | 2009-05-26 | 2015-05-19 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US20220315555A1 (en) | 2009-05-26 | 2022-10-06 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US20140189897A1 (en) | 2011-06-21 | 2014-07-03 | Mayo Foundation For Medical Education And Research | Transgenic animals capable of being induced to delete senescent cells |
| BR112014014529A2 (pt) | 2011-12-13 | 2019-09-24 | Buck Inst For Res On Aging | métodos para melhorar terapias médicas |
| US20150064137A1 (en) | 2012-04-17 | 2015-03-05 | Kythera Biopharmaceuticals, Inc. | Use of engineered viruses to specifically kill senescent cells |
| KR101719893B1 (ko) | 2012-05-22 | 2017-03-24 | 제넨테크, 인크. | Ｎ-치환된 벤즈아미드 및 통증의 치료에서 이들의 용도 |
| EP2870140B8 (en) | 2012-07-09 | 2016-09-28 | Lupin Limited | Tetrahydroquinazolinone derivatives as parp inhibitors |
| WO2014020041A1 (en) | 2012-08-02 | 2014-02-06 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer |
| WO2014020043A1 (en) | 2012-08-02 | 2014-02-06 | Bayer Pharma Aktiengesellschaft | Combinations for the treatment of cancer |
| US9901080B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells |
| US9901081B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse for determining the role of senescent cells in cancer |
| WO2015116735A1 (en) | 2014-01-28 | 2015-08-06 | Mayo Foundation For Medical Education And Research | Methods and combinations for killing senescent cells and for treating senescence-associated diseases and disorders |
| US20190269675A1 (en) | 2014-01-28 | 2019-09-05 | Buck Institute for Research and Aging | Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents |
| CA2939121C (en) | 2014-01-28 | 2020-11-24 | Mayo Foundation For Medical Education And Research | Effective treatment of osteoarthritis, pulmonary disease, ophthalmic disease, and atherosclerosis by removing senescent cells at the site of the disease |
| US10328058B2 (en) | 2014-01-28 | 2019-06-25 | Mayo Foundation For Medical Education And Research | Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques |
| KR101643280B1 (ko) * | 2014-09-02 | 2016-07-28 | 한국원자력의학원 | 항암 효과, 방사선 병용치료 효과 및 당뇨병 치료 효과를 갖는 피페리딘카복사마이드 유도체 및 이의 의학적 용도 |
| US10195213B2 (en) | 2015-03-13 | 2019-02-05 | Unity Biotechnology, Inc. | Chemical entities that kill senescent cells for use in treating age-related disease |
| CN108602770B (zh) * | 2015-11-27 | 2022-02-08 | 大鹏药品工业株式会社 | 新型联苯化合物或其盐 |
| KR102359439B1 (ko) * | 2017-03-31 | 2022-02-09 | (주)아모레퍼시픽 | 벤조산아마이드 화합물 및 사이클로덱스트린 용해보조제를 포함하는 조성물 |
| WO2018216795A1 (ja) * | 2017-05-26 | 2018-11-29 | 大鵬薬品工業株式会社 | 新規なビフェニル化合物を用いた抗腫瘍効果増強剤 |
| GB201716871D0 (en) | 2017-10-13 | 2017-11-29 | Inst Of Cancer Research: Royal Cancer Hospital | Compounds |
| WO2019195063A1 (en) * | 2018-04-03 | 2019-10-10 | Merck Sharp & Dohme Corp. | Aza-benzothiophene compounds as sting agonists |
| SI3788042T1 (sl) | 2018-04-29 | 2025-06-30 | Beigene Switzerland Gmbh | Zaviralci BCL-2 |
| RU2693378C1 (ru) * | 2018-10-02 | 2019-07-02 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ онкологии им. Н.Н. Блохина" Минздрава России) | Фармацевтическая композиция, проявляющая цитотоксическое действие в отношении клеток рака мочевого пузыря человека |
| JP7740994B2 (ja) * | 2019-06-10 | 2025-09-17 | アーデーセー セラピューティクス ソシエテ アノニム | 抗ｃｄ１９抗体薬物複合体とｐｉ３ｋ阻害剤又は二次薬剤を含む併用治療 |
| WO2021110102A1 (en) * | 2019-12-02 | 2021-06-10 | Beigene, Ltd. | Methods of cancer treatment using bcl-2 inhibitor |
| WO2021208963A1 (en) | 2020-04-15 | 2021-10-21 | Beigene, Ltd. | Bcl-2 inhibitor |
| US20240166644A1 (en) * | 2021-02-01 | 2024-05-23 | Ascentage Pharma (Suzhou) Co., Ltd. | Sulfonyl benzamide derivatives as bcl-2 inhibitors |
| WO2022198069A1 (en) | 2021-03-19 | 2022-09-22 | Eil Therapeutics, Inc. | Compounds having ((3-nitrophenyl)sulfonyl)acetamide as bcl-2 inhibitors |
| WO2024032776A1 (en) * | 2022-08-12 | 2024-02-15 | Fochon Biosciences, Ltd. | Compounds as bcl-2 inhibitors |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5892655A (ja) * | 1981-11-27 | 1983-06-02 | Otsuka Chem Co Ltd | カ−バメイト系誘導体、その製造方法及びその誘導体を有効成分として含有する殺虫剤 |
| MY115155A (en) | 1993-09-09 | 2003-04-30 | Upjohn Co | Substituted oxazine and thiazine oxazolidinone antimicrobials. |
| EP1019385B1 (en) | 1995-09-15 | 2004-01-14 | PHARMACIA & UPJOHN COMPANY | Aminoaryl oxazolidinone n-oxides |
| US20030220234A1 (en) | 1998-11-02 | 2003-11-27 | Selvaraj Naicker | Deuterated cyclosporine analogs and their use as immunodulating agents |
| GB9918037D0 (en) | 1999-07-30 | 1999-09-29 | Biochemie Gmbh | Organic compounds |
| US6720338B2 (en) * | 2000-09-20 | 2004-04-13 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| AR031130A1 (es) * | 2000-09-20 | 2003-09-10 | Abbott Lab | N-acilsulfonamidas promotoras de la apoptosis |
| US20050049594A1 (en) * | 2001-04-20 | 2005-03-03 | Wack Michael A. | Dual locking plate and associated method |
| ATE335722T1 (de) * | 2001-06-06 | 2006-09-15 | Lilly Co Eli | Benzoylsulfonamide und sulfonylbenzamidine zur verwendung als antitumor-mittel |
| AU4235802A (en) * | 2002-05-20 | 2003-11-27 | Andreas Krumbacher | Combinations flexible apparatus (multiple flexibletrack) |
| EP1565438B1 (en) * | 2002-11-22 | 2007-10-17 | Eli Lilly And Company | Antitumor benzoylsulfonamides |
| JP4336678B2 (ja) | 2003-09-04 | 2009-09-30 | 株式会社日立超エル・エス・アイ・システムズ | 半導体装置 |
| US8614318B2 (en) * | 2003-11-13 | 2013-12-24 | Abbvie Inc. | Apoptosis promoters |
| WO2005049593A2 (en) * | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| US7973161B2 (en) * | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
| US7767684B2 (en) * | 2003-11-13 | 2010-08-03 | Abbott Laboratories | Apoptosis promoters |
| PL1737850T3 (pl) | 2004-04-19 | 2008-02-29 | Symed Labs Ltd | Nowy sposób wytwarzania linezolidu i związków pokrewnych |
| WO2005117543A2 (en) * | 2004-05-26 | 2005-12-15 | Abbott Laboratories | N-sulfonylcarboximidamide apoptosis promoters |
| DE602004020812D1 (de) | 2004-07-20 | 2009-06-04 | Symed Labs Ltd | Neue zwischenprodukte für linezolid und verwandte verbindungen |
| US7511013B2 (en) | 2004-09-29 | 2009-03-31 | Amr Technology, Inc. | Cyclosporin analogues and their pharmaceutical uses |
| US20060088886A1 (en) * | 2004-10-25 | 2006-04-27 | Anlong Ouyang | Topiramate analogs |
| DK1888550T3 (da) * | 2005-05-12 | 2014-09-29 | Abbvie Bahamas Ltd | Apoptosepromotorer |
| TW200716636A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
| US7514068B2 (en) | 2005-09-14 | 2009-04-07 | Concert Pharmaceuticals Inc. | Biphenyl-pyrazolecarboxamide compounds |
| US7601844B2 (en) * | 2006-01-27 | 2009-10-13 | Bristol-Myers Squibb Company | Piperidinyl derivatives as modulators of chemokine receptor activity |
| US8796267B2 (en) | 2006-10-23 | 2014-08-05 | Concert Pharmaceuticals, Inc. | Oxazolidinone derivatives and methods of use |
| WO2008064116A2 (en) * | 2006-11-16 | 2008-05-29 | Abbott Laboratories | Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection |
| BRPI0807813A2 (pt) | 2007-02-15 | 2014-08-05 | Hoffmann La Roche | 2-amino-oxazolinas como ligantes de taar1 |
| WO2008131259A1 (en) | 2007-04-19 | 2008-10-30 | Concert Pharmaceuticals Inc. | Deuterated morpholinyl compounds |
| US7531685B2 (en) | 2007-06-01 | 2009-05-12 | Protia, Llc | Deuterium-enriched oxybutynin |
| WO2009035598A1 (en) | 2007-09-10 | 2009-03-19 | Concert Pharmaceuticals, Inc. | Deuterated pirfenidone |
| WO2009036035A1 (en) * | 2007-09-10 | 2009-03-19 | Curis, Inc. | Bcl-2 inhibitors |
| US20090118238A1 (en) | 2007-09-17 | 2009-05-07 | Protia, Llc | Deuterium-enriched alendronate |
| US20090088416A1 (en) | 2007-09-26 | 2009-04-02 | Protia, Llc | Deuterium-enriched lapaquistat |
| US20090082471A1 (en) | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched fingolimod |
| EP2209774A1 (en) | 2007-10-02 | 2010-07-28 | Concert Pharmaceuticals Inc. | Pyrimidinedione derivatives |
| WO2009051782A1 (en) | 2007-10-18 | 2009-04-23 | Concert Pharmaceuticals Inc. | Deuterated etravirine |
| US20090105338A1 (en) | 2007-10-18 | 2009-04-23 | Protia, Llc | Deuterium-enriched gabexate mesylate |
| AU2008317375B2 (en) | 2007-10-26 | 2013-02-28 | Concert Pharmaceuticals, Inc. | Deuterated darunavir |
| KR101585848B1 (ko) * | 2007-11-16 | 2016-01-15 | 애브비 인코포레이티드 | 관절염의 치료 방법 |
| US20100160322A1 (en) * | 2008-12-04 | 2010-06-24 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US8563735B2 (en) * | 2008-12-05 | 2013-10-22 | Abbvie Inc. | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| SG172393A1 (en) * | 2009-01-19 | 2011-07-28 | Abbott Lab | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| NZ593593A (en) * | 2009-01-19 | 2013-11-29 | Abbvie Inc | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
-
2011
- 2011-03-10 KR KR1020127027672A patent/KR20130040834A/ko not_active Ceased
- 2011-03-10 SG SG10201406608YA patent/SG10201406608YA/en unknown
- 2011-03-10 ES ES11709579.4T patent/ES2553143T3/es active Active
- 2011-03-10 MX MX2012011086A patent/MX2012011086A/es active IP Right Grant
- 2011-03-10 HR HRP20151218TT patent/HRP20151218T1/hr unknown
- 2011-03-10 EP EP15178279.4A patent/EP2957558A3/en not_active Withdrawn
- 2011-03-10 RS RS20150756A patent/RS54388B1/sr unknown
- 2011-03-10 DK DK11709579.4T patent/DK2550258T3/en active
- 2011-03-10 PT PT117095794T patent/PT2550258E/pt unknown
- 2011-03-10 RU RU2012145298/04A patent/RU2568611C2/ru not_active IP Right Cessation
- 2011-03-10 RU RU2015141713A patent/RU2015141713A/ru unknown
- 2011-03-10 JP JP2013501293A patent/JP5959501B2/ja not_active Expired - Fee Related
- 2011-03-10 CA CA2792276A patent/CA2792276A1/en not_active Abandoned
- 2011-03-10 AU AU2011229862A patent/AU2011229862B2/en not_active Ceased
- 2011-03-10 HU HUE11709579A patent/HUE026241T2/en unknown
- 2011-03-10 CN CN201510587254.2A patent/CN105218483A/zh active Pending
- 2011-03-10 WO PCT/US2011/027895 patent/WO2011119345A2/en not_active Ceased
- 2011-03-10 NZ NZ602055A patent/NZ602055A/en not_active IP Right Cessation
- 2011-03-10 NZ NZ628298A patent/NZ628298A/en not_active IP Right Cessation
- 2011-03-10 BR BR112012024382A patent/BR112012024382A2/pt not_active IP Right Cessation
- 2011-03-10 PL PL11709579T patent/PL2550258T3/pl unknown
- 2011-03-10 SG SG2012068615A patent/SG184094A1/en unknown
- 2011-03-10 SI SI201130660T patent/SI2550258T1/sl unknown
- 2011-03-10 EP EP14160660.8A patent/EP2757105A1/en not_active Withdrawn
- 2011-03-10 CN CN201180015915.4A patent/CN102947283B/zh not_active Expired - Fee Related
- 2011-03-10 EP EP11709579.4A patent/EP2550258B1/en active Active
- 2011-03-16 US US13/049,569 patent/US8188077B2/en not_active Expired - Fee Related
- 2011-03-25 TW TW105106938A patent/TW201623291A/zh unknown
- 2011-03-25 TW TW100110483A patent/TWI535713B/zh not_active IP Right Cessation
-
2012
- 2012-04-27 US US13/458,968 patent/US8343967B2/en not_active Expired - Fee Related
- 2012-09-04 IL IL221771A patent/IL221771A/en not_active IP Right Cessation
- 2012-09-12 ZA ZA2012/06837A patent/ZA201206837B/en unknown
-
2013
- 2013-06-06 HK HK15100726.4A patent/HK1200444A1/en unknown
-
2014
- 2014-03-25 IL IL231702A patent/IL231702A0/en unknown
-
2016
- 2016-01-15 SM SM201600016T patent/SMT201600016B/it unknown
- 2016-06-17 HK HK16107017.6A patent/HK1219092A1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20151218T1 (hr) | Sredstva za induciranje apoptoze za lijeäśenje raka te imunih i autoimunih bolesti | |
| JP2013523636A5 (enExample) | ||
| US9662339B2 (en) | Benzodioxane inhibitors of leukotriene production for combination therapy | |
| US8946203B2 (en) | Benzodioxane inhibitors of leukotriene production | |
| US8389743B2 (en) | Histamine-3 receptor antagonists | |
| ES3013457T3 (en) | Benzamide compounds as bci inhibitors for the treatment of hiv | |
| US9133146B2 (en) | Benzodioxane inhibitors of leukotriene production | |
| CA2513915C (en) | New arylpiperazinyl compounds | |
| HRP20150925T1 (hr) | Agensi koji induciraju apoptozu za lijeäśenje raka te imunih i autoimunih bolesti | |
| RU2376303C2 (ru) | Производные аминопиперидина, их получение и применение в терапии | |
| JP2023123613A (ja) | ユビキチン特異的ペプチダーゼ３０の阻害 | |
| HRP20131052T1 (hr) | Agonisti mglu2 | |
| CA2679198A1 (en) | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases | |
| RU2011107437A (ru) | Ингибиторы кинуренин-3-моноксигеназы | |
| RU2014141579A (ru) | Гетероциклические соединения в качестве ингибиторов бета-лактамаз | |
| CA2672373A1 (en) | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases | |
| JP2013525318A5 (enExample) | ||
| KR20140081884A (ko) | Lsd1 억제제로서 (헤테로)아릴 사이클로프로필아민 화합물 | |
| AU2021263568A1 (en) | BCL-2 protein inhibitors | |
| BR112018014296B1 (pt) | Derivados de 3-(carboximetil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano | |
| JP2021098692A (ja) | 核内受容体に対して活性の化合物 | |
| HRP20030298A2 (en) | Bridged piperazine derivatives | |
| RU2007128082A (ru) | Новые производные циклогексана | |
| DE60319686T2 (de) | Cyanamide als reversible hemmer von cystein proteasen | |
| EP3758696A1 (en) | [1,2,4]triazolo[1,5-a]pyrimidine compounds and use in stabilizing microtubules |